Windgap Medical said in a regulatory filing today that it raised a debt-and-options round worth $2.9 million for the epinephrine auto-injector it’s developing.
Somerville, Mass.-based Windgap is working on a device that would mix a dry formulation of the drug into solution, then inject it into a patient suffering from anaphylaxis due to an acute allergy attack.
The device is designed to be smaller than the market leading EpiPen made by Mylan (NSDQ:MYL) and eliminate the shelf life problems associate with liquid epinephrine.
The funding round involved 46 unnamed investors, according to the filing.
